Primary CNS lymphoma (PCNSL) is a diffuse large B-cell lymphoma (DLBCL) confined to the CNS. We performed a genome-wide gene expression comparison between PCNSL and nonCNS DLBCL, the latter consisting of both nodal and extranodal DLBCL (nDLBCL and enDLBCL), to identify a "CNS signature". Pathway analysis with the program 
Introduction
PCNSL is a DLBCL with a tropism for the CNS microenvironment and is confined to the CNS. Biologically, PCNSL is interesting in that it is a B cell lymphoma in the CNS where very few B lymphocytes, if any, are found under normal circumstances 1 . Some studies have indicated that PCNSL is of germinal center B cell origin 2, 3 . According to a gene expression study, nonCNS DLBCL has been classified into 3 groups: germinal center B cell type (GCB), activated B cell type (ABC), and type 3 4 . PCNSL has been shown to have immunophenotypic features of ABC 5 . These findings taken together indicate that PCNSL develops from a B cell which has been exposed to a germinal center influence outside the CNS. Therefore, understanding the mechanisms that mediate B cell migration and adaptation to the CNS microenvironment are important goals in research into the biology of PCNSL.
PCNSL remains incurable in most patients 6 . Obviously, a better understanding of its biology is crucial to improve the prognosis. To this end, many studies, including DNA microarray studies, have been performed comparing PCNSL to nonCNS DLBCL, usually of nodal type. Of these, the largest microarray study to date compared PCNSL to nodal DLBCL and revealed several important molecular properties, including features linked to angiotropism 7 . In our opinion, it is important to contrast PCNSL with all types of nonCNS DLBCL (both nDLBCL and enDLBCL), on a genomic scale, and to employ in-depth bioinformatic analysis, especially pathway analysis, to identify the "CNS signature". We performed such a study and revealed new biological insights.
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Materials and Methods
Study subjects. Fresh frozen samples of PCNSL, nDLBCL, and enDLBCL from immunocompetent patients were obtained under the protocol approved by Institutional Review Board of Mayo Clinic. These samples were surplus tissues after the establishment of definitive pathologic diagnosis. The pathologic diagnosis was confirmed by central pathology review (DMM). Totals of 13 PCNSL, 11 nDLBCL, and 19 enDLBCL were used in this study. For CNS tumors, 11 of 13 were stereotactic needle biopsies; the other two were from resections. The quality of the samples was ascertained by CD-20 immunohistochemical stain; generally an estimated 80% or more content of B-cells was observed. The enDLBCL samples originated from spleen (1), tonsil (4), adenoid (1), skin (1), bone (3), stomach (1), liver (1), testes (2) , ovary (1), epidural (1), pericardium (1), thyroid (1) , and pleural (1).
Microarray protocols. Total RNA was extracted from the dissected lymphoma tissue using a kit from Qiagen (Rneasy mini kit; Valencia, CA). A fraction of the total RNA was used to perform a quality check for RNA integrity using the Bioanalyzer 2100 (Agilent). Only samples yielding profiles of intact total RNA (retention of both ribosomal bands and the broad central peak of mRNA) were used for the microarray analyses reported in this paper. The mRNA in the sample was amplified with a kit from Arcturus Engineering (RiboAmp HS RNA Amplification Kit). The resulting aRNA (amplified RNA) preparations were labeled either with Alexa Fluor 555 (lymphoma sample) or Alexa Fluor 647 (reference RNA) from Molecular Probes (Eugene, Oregon). The reference RNA was the "Universal" human RNA from Stratagene. The Alexa dyes have been shown to have reduced labeling bias 8 . The labeled samples were hybridized to Agilent Human Genomic Oligo 60-mer microarrays (41,061 probes) in Agilent microarray chambers (G2534A) at 60 deg C for 17 hours. After washing and drying, the array was scanned for analysis in a confocal laser scanner (ScanArray Express, Packard Bioscience, Perkin-Elmer) and Imagene software (version 6; BioDiscovery, Inc.) was used to process the images.
Validation of microarray results. It was acccomplished by using quantitative RT-PCR
(detailed protocol is in the Supplemental Methods). Briefly, a portion of cDNA that was also For personal use only. on April 7, 2017 . by guest www.bloodjournal.org From used for microarray experiments was used to quantitate 10 genes: ATP5J (NM_001685.4),
TFPI2 (NM_006528.2) and GAPDH (NM_002046.3). The level of GAPDH was used as a reference for obtaining the levels of the other mRNAs, and the ratios of CNS/nodal and CNS/extranodal were calculated. These ratios were then plotted vs ratios determined from the microarray data and the correlation coefficient determined after linear regression. We also performed immunohistochemistry (IHC) on SPP1 and CHI3L1(detailed protocol in the Supplemental Methods).
Bioinformatics methods: Clustering and parametric tests. The gene list used was ~11,500 in number (genes "present" on 35 or 43 arrays). The LOWESS method of normalization was used. In GeneSpring, unsupervised clustering of genome-wide expression profiles of PCNSL and non-CNS nodal and extranodal DLBCL was performed using "standard correlation" metric in GeneSpring (v.7.2). Genes identified by Fisher Discriminant Analysis (see below)
were also used to cluster the 43 samples, using Cluster 3.0. 9 The clustering was performed using uncentered correlation and complete linkage using genes identified in the FDA analysis for genes separating the samples into two classes (CNS and nonCNS) at p<0.01.
Bioinformatics methods: Pathway analysis. Data were imported into GeneSpring (version 7.2, Silicon Genetics, Perkin-Elmer) where LOWESS normalization was performed.
The data were trimmed to those genes that were present on at least 35 of the 43 arrays, about 11,500 in number. In effect, this processing removed most of the weaker signals. Since additional global normalization did not change the SigPathway results substantively (not shown), the results presented in this paper are from data with only LOWESS normalization performed. In this type of normalization the ratios of the two channels on each array are adjusted to correct for nonlinearity between the ratios and signal intensity. The data were exported into Microsoft Excel, then to Star Calc, and saved in "comma-separated value" format. For pathway analysis, the data were imported into R (version 2. 
Results
Initial characterization of the microarray data. In the final dataset, there were a total of 43 high quality lymphoma samples that produced reliable microarray data, from which filtering yielded about 11,500 genes that were present on at least 35 arrays, a reasonable compromise that optimized both gene numbers and data quality. A standard clustering of these ~1l,500 filtered and LOWESS-normalized genes is shown in Fig. 1 , where the array data are averaged according to the three phenotypes. Within the basis list of ~11,500 genes, there were 50 genes that were significantly (Student's t-test; p<0.05) expressed at two-fold or greater difference between the PCNSL and nonCNS DLBCL ( Table 1) .
For validation of the microarray data, we performed qRT-PCR for a set of 10 genes, which included several extracellular matrix (ECM)-related genes (that will be shown below to be important), several others of interest, and GAPDH. There was excellent agreement between the microarray and qRT-PCR data. 
Pathway analysis of the DLBCL gene expression dataset The bioinformatics program
SigPathway was used to identify those gene sets that were most powerful in contrasting phenotypes 10 . The PCNSL was contrasted pairwise with nonCNS DLBCL (=nDLBCL+enDLBCL), nDLBCL, and enDLBCL for a total of three comparisons ( Tables 2-4; these tables are abbreviated in the main text; full versions are included in the Supplemental Tables). Table 2 shows the pathway analysis results for the contrast between the 13 CNS samples versus 30 "nonCNS" samples (nDLBCL and enDLBCL combined). This contrast led to discoveries of primary importance in this study: assessment of biological pathways unique to PCNSL. Table 3 contrasts CNS with nDLBCL samples; Examination of these three tables reveals that the PCNSL phenotype differentially expresses two major types of ontological gene sets, one type that primarily sets apart the PCNSL phenotype from both nDLBCL and enDLBCL combined, and other gene sets that differentiate PCNSL from each nonCNS group, either nDLBCL or enDLBCL separately. Gene sets of the first type will appear in all three tables. For example, in the PCNSL vs nonCNS contrast ( Table   2 (extracellular matrix/adhesion molecules). Nine (9) of these 11 gene sets also appear in the PCNSL vs nDLBCL contrast (Table 3) , while ten (10) of these 11 gene sets also appear in the PCNSL vs enDLBCL contrast ( Table 4) . After removing duplicate listings, there were 244 unique genes in these 11 gene sets listed from Table 2 . Their expression levels are plotted (in black) overlying the ~11,500 total genes (shown in color) in the scatter-plot in Fig. 3A . The normalized levels for non-CNS samples (n=30) were averaged and plotted against averages of the normalized levels for the PCNSL samples (n=13). Of these 244 ECM and adhesion-related genes (plotted in black), 170 lie above the line of equivalent expression, indicating relatively higher expression in nonCNS samples; 74 genes are expressed at higher levels in the PCNSL samples. Several of these ECM and adhesion-related genes are labeled in Fig. 3A . Notably, SPP1 (secreted phosphoprotein 1, osteopontin; NM_000582) and CHI3L1 (chitinase-3 like 1, cartilage glycoprotein-39, ECM structural hydrolase; NM_001276) are expressed at much higher levels in PCNSL (9.7-fold and 2.7-fold, PCNSL>nonCNS, respectively). Several other ECMrelated genes labeled in Fig. 3A are expressed higher in the nonCNS samples: TFP12 (tissue factor pathway inhibitor 2; NM_006528; 5.1-fold nonCNS>PCNSL), FBN1 (fibrillin 1; NM_000138; 3.4-fold nonCNS>PCNSL), COL1A2 (collagen type 1 alpha2; NM_000089; 3.7-For personal use only. on April 7, 2017 . by guest www.bloodjournal.org From fold nonCNS>PCNSL), and LUM (lumican, collagen binding protein; NM_002345; 3.6-fold nonCNS>PCNSL). Differential expression of genes in sterol biosynthesis pathway also appears to be part of the CNS pathway signature as this pathway is found to be significant in all three contrasts.
Other groupings of ontological gene sets differentiate the PCNSL from either enDLBCL or nDLBCL separately. For example, The gene sets 10, 15, and 16 in Table 3 , where CNS and nDLBCL are contrasted, are involved in cytokine production; these groups do not appear in Table 4 , where CNS and enDLBCL are contrasted. Only gene set 41 in Table 4 is linked to cytokines, and it concerns receptor functions, not cytokine production. There are 92 unique genes in gene sets 10, 15, and 16 combined; they are plotted in black overlying all ~11,500 genes used in the analysis (plotted in color) in Fig. 3B . Several of individual genes in this composite are labeled: S100B, IRF4, CXCL13, BMP7, BC 027979, and IL8 are elevated two-fold or more in the PCNSL; TNFSF17, TNFSF13B, and VEGFC are elevated in nDLBCL at least two-fold with respect to CNS samples. Another grouping of gene sets in Table 3 None of the gene sets appear in the contrast between CNS and EN ( Table 4) . The contrast PCNSL vs nDLBCL also showed significant differential expression of many metabolic pathways.
Of these, lipoprotein-related pathways are absent in PCNSL vs enDLBCL contrast.
The PCNSL vs enDLBCL contrast (Table 4) , exhibits several gene sets associated with apoptosis (6, 17, 32, 33, 34, 35 ,) that do not appear in the PCNSL vs nDLBCL contrast. These seven (7) gene sets contain 159 unique genes, which are plotted (in black) overlying all ~11,500 genes in the basis (color) in Fig. 3C . Several genes of interest in this composite are labeled: S100B, AF 217966 (CED4-like death effector filament forming), AK074291 (Oligo capping), which are relatively higher in expression in the PCNSL; U45880 (X-linked inhibitor of apoptosis protein, XIAP), S56204 (insulin-like growth factor binding protein 3), and CAPN2 (calpain type 2), which are expressed two-fold or more higher in the enDLBCL relative to PCNSL. Moreover, certain chromatin and chromosome related pathways (5, 7, 10, 21, 24) showed significant differential expression between PCNSL and enDLBCL. They are conspicuously absent from PCNSL vs nDLBCL contrast. The contrast results for PCNSL vs enDLBCL also reveal that certain aspects of amine metabolism that separate these two phenotypes (gene sets 19 and 25). 
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Fisher discriminant analyses of the DLBCL gene expression dataset. When FDA was applied to the discrimination of two classes, CNS from nonCNS, with the criterion of p<0.01 reliability, 172 genes were identified, and these included seven (7) of the ECM and adhesion-related group, three (3) of the cytokine group, and four (4) of the apoptosis group.
Clustering (using Cluster 3.0) with these 172 genes completely separated the CNS samples from the nonCNS samples (Fig. 4 ; the ratio data were log-transformed and clustered with Cluster 3.0 using uncentered correlation and complete linkage. The right-hand portion of Fig. 4 shows enlarged views of several gene clusters of interest, including SPP1 (Fig. 4A) , DDR1 and DKK1 (Fig. 4B) , a group of ECM-related genes COL6A1, COL1A2, and LAM4 (Fig. 4C) , and a cluster containing CRYAB (Fig. 4D) . Careful examination of the main clustering results reveals patterns of expression that separate most of the samples according to the three main phenotypes ("Brain" [CNS], nodal, and extranodal), as well as patterns that subdivide the CNS phenotype into two subclasses.
When FDA was performed to identify genes that separated three classes (CNS, nodal, extranodal) at p<0.01, 144 genes were identified. The gene list was similar to that from the twoclass analysis and contained many of the genes in Table 1 and in the SigPathway analyses (not shown). In this analysis, the CNS phenotypes was separated into two adjacent groups one of which contained only CNS samples (n=8), the other of which contained the other 5 CNS samples and one EN sample (not shown).
Immunohistochemical studies of DLBCL. Two genes that were strongly and reliably upregulated in PCNSL were selected for immunohistochemistry (IHC). Expression of osteopontin (SPP1) and chitinase-3 like1 (CHI3L1) proteins was studied in DLBCL samples from PCNSL(n=15, which comprised the 5 used in the microarray study plus 10 additional), nDLBCL(n=10 with 5 samples used in the microarray study plus 5 additional), and enDLBCL(n=7 with 5 samples used in the microarray study plus 2 additional). The staining pattern for CHI3L1 was both cytoplasmic and nuclear but the nuclear staining was more predominant. Positive staining for CHI3L1 was seen in 73% of PCNSL and 41% of non-CNS DLBCL. Heavy staining was present in 40% of PCNSL and 18% of non-CNS DLBCL.
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Discussion
We have identified alterations in gene expression signature of DLBCL that correlate with anatomic locations, using a statistically powerful method, SigPathway, that makes use of the fact that many if not most genes are co-regulated according to activation or repression of particular pathways. Most important in the present study was the finding that the PCNSL expresses a unique set of ECM and adhesion-related pathways and genes when contrasted with non-CNS DLBCL. This "CNS signature" for PCNSL was readily attained by contrasting PCNSL with the all the non-CNS DLBCL combined (nDLBCL + enDLBCL). Similar findings were also seen when PCNSL was contrasted with either nDLBCL or enDLBCL, further indicating that these findings are uniquely important for PCNSL. The most significant gene set found in pathway analysis was the ECM-receptor pathway, suggesting that the interaction between the CNS microenvironment and lymphoma cells is of great importance for PCNSL. At the single gene expression level, we also found significant, differential expression of numerous ECM and adhesion-related genes. In addition, we demonstrated the upregulation in PCNSL of two important ECM-related genes, SPP1 and CHI3L1, at the protein level.
The differential expression of ECM related genes, especially adhesion genes, has been long suspected in PCNSL but has not been proven in previous studies [14] [15] [16] . The reason for this may be that most of the genes in these pathways do not differentially express at a statistically significant level when tested individually. However, when they are analyzed in groups by SigPathway, many ECM-related pathways, including focal adhesion pathways, are found to be significantly implicated in PCNSL biology. Thus, the SigPathway results demonstrate the power of pathway analysis to infer statistically reliable biological mechanisms in DLBCL, in particular indicating the existence of a unique expression profile for PCNSL. The results of the FDA analyses also provide support for the idea of a unique PCNSL signature. FDA is a matrix decomposition method that identifies those genes whose composite expression patterns are most powerful in distinguishing the phenotypes, and is mathematically very different from the methods of SigPathway. From the basis dataset of ~11,500 genes, subsets of <200 genes in number were identified by FDA that have expression patterns that can completely, or nearly invasion, metastasis, and regulation of cytokine expression and angiogenesis 17, 18 . A high level of expression of SPP1 has been associated with aggressive cancers and poor prognosis 17 . Our immunohistochemical finding of predominantly nuclear staining pattern in PCNSL cells is quite unique, as SPP1 staining is usually cytoplasmic in other malignant tumors 19 . The nuclear localization of SPP1 has been linked to cellular proliferation 20 . SPP1 has been found to be upregulated in other CNS diseases such as multiple sclerosis 21 , and glioblastoma multiforme and astrocytomas 17 . It appears that SPP1 plays an important role in pathogenesis of CNS diseases.
To our knowledge, this is the first report of significant upregulation of SPP1 in PCNSL. It is noteworthy that SPP1 has not been previously reported to be expressed significantly in B cells.
Our IHC experiments show that CHI3L1 expression is higher in PCNSL as compared to non-CNS DLBCL. CHI3L1 (YKL-40) is an ECM-related gene widely implicated in the biology of several types of cancer. It has a role in cancer cell proliferation, differentiation, survival, invasiveness, metastasis, angiogenesis and remodeling of extracellular matrix surrounding the tumor 22 . Highest serum levels of CHI3L1 are found in patients with metastatic cancer with the shortest recurrence-free interval and shortest overall survival 22 . The presence of immunohistochemically detected CHI3L1 in breast cancer is associated with a poor prognosis 23 .
Other significantly up-regulated ECM/adhesion genes in our study include DDR1 and TACSTD1 (EpCAM). DDR1 is a member of a novel family of receptor tyrosine kinases thought to play a role in cell adhesion 24 . It has been shown to be consistently and selectively expressed in human brain tumors 25 . TACSTD1 (EpCAM) is a cell adhesion molecule expressed by a variety of carcinomas 26 . It is also expressed in normal retina and retinoblastoma 27 .
Several previous studies of PCNSL are relevant to other findings in our experiments.
Upregulated CXCL13, a B cell attracting chemokine, has been shown previously to occur in PCNSL 28 . We also found that RGS13, which regulates germinal center B cell responsiveness to Other up-regulated genes in our dataset have been implicated previously in cancer biology. TCL1A has been implicated in lymphatic leukemias and lymphomas 30 . CRYAB has been found to be upregulated in cancers and correlated with risk of cancer recurrence 31, 32 . DKK3
has been implicated in cancer, although its exact role has not been clarified 33 . We found that MGST1, one of the glutathione S-transferases, is upregulated in PCNSL. Glutathione Stransferases have been implicated in lymphomas 34 and chemotherapy resistance 35 . S100B has been implicated in neoplasia, especially in melanoma 36, 37 . TF was the second most upregulated gene for PCNSL. It has been shown to act as an autocrine regulator of cellular proliferation 38 .
The receptor for transferrin is frequently expressed in non-Hodgkin's lymphomas 39 .
We 
CHI3L1
, and MUM1 is consistent with the known aggressive clinical behavior of PCNSL. SPP1 and CHI3L1 have been associated with aggressive metastatic cancers, suggesting that PCNSL has an aggressive metastatic cancer phenotype. Because our approach contrasted PCNSL with a wide spectrum of nonCNS DLBCL on a genomic scale with in-depth bioinformatic analysis, the gene expression signature identified in our study may represent a true "CNS signature".
For 
Financial Conflict of Interest:
None of the authors has any competing financial interests. Since the two-color array method involved a reference standard, the colors do not represent actual gene expression levels in the tumor samples, but rather the ratio of the tumor mRNA to the reference mRNA. The LOWESS method of normalization was used. To the right of the cluster are shown 10 genes of interest enlarged from the cluster; the colored bars correspond to the three phenotypes identified at the bottom of the cluster ("Brain", "Extranodal", and "Nodal"; left to right). SPP1 (osteopontin), CHI3L1 (chitinase-3 like 1), IRF4 (MUM1), S100B (S100 calcium binding protein beta), SERPINA3 (serine proteinase inhibitor, clade A, member 3), CRYAB (crystallin alpha B), LUM (lumican), COL1A2 (collagen type 1 alpha 2), COL6A1
(collagen type 6 alpha 1), LAMA4 (laminin alpha 4). For personal use only. on April 7, 2017 . by guest www.bloodjournal.org From
Figure 1
Figure 2.
For personal use only. on April 7, 2017 . by guest www.bloodjournal.org From 
